LEADER 03361nam  2200637 a 450 
001 9910784993303321
005 20200520144314.0
010   $a1-281-27620-0
010   $a9786611276201
010   $a3-540-78248-6
024 7 $a10.1007/978-3-540-78248-3
035   $a(CKB)1000000000406917
035   $a(EBL)373069
035   $a(OCoLC)261325810
035   $a(SSID)ssj0000266519
035   $a(PQKBManifestationID)11191593
035   $a(PQKBTitleCode)TC0000266519
035   $a(PQKBWorkID)10302100
035   $a(PQKB)10049316
035   $a(DE-He213)978-3-540-78248-3
035   $a(MiAaPQ)EBC373069
035   $a(Au-PeEL)EBL373069
035   $a(CaPaEBR)ebr10223458
035   $a(CaONFJC)MIL127620
035   $a(PPN)123745896
035   $a(EXLCZ)991000000000406917
100   $a20081029d2008      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aValuation in life sciences$b[electronic resource] $ea practical guide /$fBoris Bogdan, Ralph Villiger
205   $a2nd ed.
210   $aHeidelberg $cSpringer$d2008
215   $a1 online resource (344 p.)
300   $aDescription based upon print version of record.
311   $a3-540-78247-8 
320   $aIncludes bibliographical references and index.
327   $aFundamentals in Life Sciences -- Basics of Valuation -- Valuation in Life Sciences -- Exercises -- Case Studies.
330   $aValuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.
606   $aValuation
606   $aBiotechnology industries$xFinance
615  0$aValuation.
615  0$aBiotechnology industries$xFinance.
676   $a332.63221
676   $a338.436151
700   $aBogdan$b Boris$01542286
701   $aVilliger$b Ralph$01542287
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910784993303321
996   $aValuation in life sciences$93794879
997   $aUNINA